JPRN-UMIN000000829已完成2 期
Dose-adjusted EPOCH therapy for the previously untreated patients of advanced peripheral T-cell lymphoma
West Japan Hematology Oncology Group0 个研究点目标入组 42 人开始时间: 2007年9月22日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 79years-old（—）
- 性别
- All
入选标准
- •(1)Histological confirmed
- •Anaplastic large cell lymphoma (ALCL) or
- •Angioimmunoblastic T-cell lymphoma (AILT) or
- •Peripheral T-cell lymphoma, unspecified (PTCL-u).
- •(2) Clinical stage of II, III, IV by Ann Arbor classification.
- •(3) Bidimensionally measurable disease
- •(4) Age: between 15 and 79.
- •(5) Performance Status: between 0 and 2.
- •(6) No organ dysfuction; neutrophil count >=1000/ml, platelet count >=75000/ml, ASTand ALT level <=3 times the upper limit of the normal range, total bilirubin level <= 2.0 mg/dl, serum creatinin level <= 2.0mg/dl, Resting ejection fraction >= 50% by UCG. SaO2 >=90% or PaO2 >=60 mmHg in room air.
- •(7) No prior chemotherapy, radiotherapy
- •(8) Understanding and agreement of written informed consent.
排除标准
- •1) Uncontrollable active infection
- •2) Complication; uncontrollable hypertension or DM, liver cirrhosis, interstitial pneumonia, pulmonary fibrosis.
- •3) Positive for HIV antibody or HBs antigen.
- •4) Have an active cancer.
- •5) Pregnant or nursing.
- •6) Psycological disorder like schizophrenia.
- •7) A patient who was judged as inappropriate for the trial
研究者
相似试验
Unknown
2 期
Trial of DA-EPOCH Regimen for NHL With HLHNHL With Hemophagocytic LymphohistiocytosisNCT01818908The First Affiliated Hospital with Nanjing Medical University50
已完成
2 期
A Phase II trial of Dose adjusted EPOCH and Rituximab therapy for newly-diagnosed DLBCL with C-MYC rearrangementC-MYC positive diffuse large B-cell lymphomaJPRN-UMIN000015972Kanagawa Clinical Oncology study Group34
已完成
2 期
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaAIDS-Related Burkitt LymphomaAtypical Burkitt/Burkitt-Like LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent Acute Lymphoblastic LeukemiaRecurrent Burkitt LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Burkitt LymphomaNCT02199184M.D. Anderson Cancer Center14
已完成
1 期
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaLeukemia-Lymphoma, Adult T-CellNCT01000285Washington University School of Medicine18
招募中
3 期
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trialDiseases [C] - Blood and lymphatic diseases [C15]DRKS00024085IVERSITÄTSKLINIKUM FREIBURG; Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation260